NCT05329545: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)
- State
- Stopped early
- Phase
- Phase 3
- People
- 20 taking part
- Started
- 23 Jun 2022
- Primary completion
- 29 Sep 2023
- Arms
- XMT-1536 (upifitamab rilsodotin)
- Results
- None posted
- 15 Apr 2022: Trial registered
- 23 Jun 2022: Trial started
- 29 Sep 2023: Trial terminated